Abstract
Multiple Myeloma (MM) is a genomically heterogeneous malignancy, characterized by a relevant mutational burden, as compared to other types of cancer. By employing a frequentist approach to define MM driver mutation, a landscape of few variants in a limited number of genes, mostly associated to survival and/or proliferative pathways (eg. KRAS, NRAS, TP53, BRAF), have been reported so far. Nevertheless, given the high genomic heterogeneity of MM plasma cells, new possible driver mutations, being rare and/or scattered across the genome, might be diluted within the genomic complexity and therefore missed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
